CHRS (Coherus Oncology) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHRS Coherus Oncology Inc CHRS
42 GF Score
Price $1.27
GF Value $0.94
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Coherus Oncology Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

CHRS
42GF Score
Coherus Oncology Inc CHRS
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Coherus Oncology (CHRS) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of $1.27 is trading 35.1% above its estimated GF Value™ of $0.94. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for CHRS:

  • Interest Received:
  • GF Value™: $0.94 vs. price of $1.27 (35.1% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges 8C5:Germany
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score

Get the complete analysis for CHRS

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.27
Price
$0.94
GF Value